Loading
NASDAQHealthcareBiotechnology
Latest quote
$31.57
−$0.35 · -1.10%
Agios Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to the research and advancement of new treatments, specifically targeting cellular metabolism and related biological fields. The company's offerings include PYRUKYND (mitapivat), a medication designed to activate both wild-type and various mutated pyruvate kinase (PK) enzymes, used in the management of hemolytic anemias. Additionally, Agios is developing AG-946, which is currently undergoing Phase I clinical studies for treating hemolytic anemias and other diseases. Established in 2007, the company's main office is located in Cambridge, Massachusetts.
Regular session
$31.57
−$0.35 · -1.10%
Regular session · ET · Market data may be delayed.
Agios Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to the research and advancement of new treatments, specifically targeting cellular metabolism and related biological fields. The company's offerings include PYRUKYND (mitapivat), a medication designed to activate both wild-type and various mutated pyruvate kinase (PK) enzymes, used in the management of hemolytic anemias. Additionally, Agios is developing AG-946, which is currently undergoing Phase I clinical studies for treating hemolytic anemias and other diseases. Established in 2007, the company's main office is located in Cambridge, Massachusetts.
Day range
Current $31.57
52-week range
Current $31.57
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
2
Overpriced
Sentiment
64
Bullish
Risk
42
Elevated Risk
Momentum
64
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Agios Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to the research and advancement of new treatments, specifically targeting cellular metabolism and related biological fields. The company's offerings include PYRUKYND (mitapivat), a medication designed to activate both wild-type and various mutated pyruvate kinase (PK) enzymes, used in the management of hemolytic anemias. Additionally, Agios is developing AG-946, which is currently undergoing Phase I clinical studies for treating hemolytic anemias and other diseases. Established in 2007, the company's main office is located in Cambridge, Massachusetts.
Day range
Current $31.57
52-week range
Current $31.57
Reported history and fiscal-year consensus
Reported history and fiscal-year consensus
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI63.84M0.00%2.3T USD0.03%$380.38+0.22%
State Street SPDR S&P Biotech ETFXBI55.66M0.55%10.11B USD0.35%$150.53+0.83%
iShares Russell 2000 ETFIWM49.6M0.06%77.7B USD0.19%$277.56-0.00%
Vanguard Morningstar Small-Cap ETFVB46.06M0.02%185.3B USD0.03%$287.67+0.01%
Vanguard Morningstar Small-Cap Growth ETFVBK26.39M0.06%44.7B USD0.05%$341.01+0.12%
Vanguard Extended Market ETFVXF23.28M0.02%95.4B USD0.05%$233.15+0.01%
iShares Russell 2000 Value ETFIWN16.46M0.12%13.75B USD0.24%$210.65-0.14%
iShares Biotechnology ETFIBB14.41M0.14%10.41B USD0.44%$202.71+1.11%Vanguard Morningstar Total Stock Market ETFVTIState Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMVanguard Morningstar Small-Cap ETFVBVanguard Morningstar Small-Cap Growth ETFVBKVanguard Extended Market ETFVXFiShares Russell 2000 Value ETFIWNiShares Biotechnology ETFIBBAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
